Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Sagimet Biosciences Inc. (SGMT)

9.95 -0.04 (-0.40%)
At close: October 22 at 4:00:00 PM EDT
10.00 +0.05 (+0.50%)
After hours: October 22 at 7:52:46 PM EDT
Trade SGMT on Coinbase
Chart Range Bar
Loading chart for SGMT
Chart does not reflect overnight price.
  • Previous Close 9.99
  • Open 10.00
  • Bid 5.84 x 200
  • Ask 10.26 x 200
  • Day's Range 9.63 - 10.15
  • 52 Week Range 4.50 - 11.45
  • Volume 1,006,569
  • Avg. Volume 1,310,616
  • Market Cap (intraday) 705.541M
  • Beta (5Y Monthly) 3.49
  • PE Ratio (TTM) --
  • EPS (TTM) -1.26
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 27.91
  • Zacks Rating Bullish

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

www.sagimet.com

16

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SGMT
68.07%
S&P 500 (^GSPC)
11.95%

1-Year Return

SGMT
33.56%
S&P 500 (^GSPC)
14.39%

3-Year Return

SGMT
101.42%
S&P 500 (^GSPC)
81.42%

5-Year Return

SGMT
35.81%
S&P 500 (^GSPC)
68.62%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -13.95M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

7.00
27.91 Average
9.95 Current
56.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/5/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 29 -> 29

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    647.07M

  • Enterprise Value

    408.88M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.53

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -16.41%

  • Return on Equity (ttm)

    -24.37%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -47.08M

  • Diluted EPS (ttm)

    -1.26

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    240.13M

  • Total Debt/Equity (mrq)

    0.76%

  • Levered Free Cash Flow (ttm)

    -27.82M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

9.95 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: